artenimol has been researched along with Rhabdomyosarcoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, B; Guo, X; Houghton, PJ; Huang, S; Huang, Z; Li, L; Liu, W; Luo, J; Luo, Y; Odaka, Y; Shang, C; Wu, Y; Yang, S; Zhang, C | 1 |
| Huang, S; Luo, Y; Odaka, Y; Shang, C; Shen, T; Wu, Y; Xu, B; Zhou, H | 1 |
2 other study(ies) available for artenimol and Rhabdomyosarcoma
| Article | Year |
|---|---|
Dihydroartemisinin Inhibits mTORC1 Signaling by Activating the AMPK Pathway in Rhabdomyosarcoma Tumor Cells.
Topics: AMP-Activated Protein Kinases; Artemisinins; Cell Line, Tumor; Humans; Mechanistic Target of Rapamycin Complex 1; Neoplasm Proteins; Rhabdomyosarcoma; Signal Transduction | 2021 |
Dihydroartemisinin inhibits the mammalian target of rapamycin-mediated signaling pathways in tumor cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Artemisinins; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Genes, p53; Humans; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Phosphoproteins; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Rhabdomyosarcoma; Signal Transduction; TOR Serine-Threonine Kinases | 2014 |